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Abstract: Staphylococcus aureus and cystic fibrosis (CF) are closely interlinked. To date, however, the
impact of S. aureus culture in CF airways on lung function and disease progression has only been
elucidated to a limited degree. This analysis aims to identify bacterial factors associated to clinical
deterioration. Data were collected during an observational prospective multi-center study following
195 patients from 17 centers. The average follow-up time was 80 weeks. S. aureus isolates (n = 3180)
were scanned for the presence of 25 virulence genes and agr-types using single and multiplex PCR.
The presence of specific virulence genes was not associated to clinical deterioration. For the agr-types
1 and 4, however, a link to the subjects’ clinical status became evident. Furthermore, a significant
longitudinal decrease in the virulence gene quantity was observed. Analyses of the plasticity of the
virulence genes revealed significantly increased plasticity rates in the presence of environmental stress.
The results suggest that the phylogenetic background defines S. aureus pathogenicity rather than
specific virulence genes. The longitudinal loss of virulence genes most likely reflects the adaptation
process directed towards a persistent and colonizing rather than infecting lifestyle.
Keywords: Staphylococcus aureus; cystic fibrosis; virulence genes; phylogeny; horizontal gene transfer
Key Contribution: A longitudinal decline in S. aureus virulence gene quantity was observed.
The presence of specific virulence genes characteristic for S. aureus was not associated to clinical
deterioration.
1. Introduction
Cystic fibrosis (CF) is the most prevalent life-shortening genetic disorder in the Caucasian
population, characterized by increased viscosity of exocrine gland secretions, congestion of physiological
outflow pathways, and consecutive cystic and fibrotic remodeling of the respective organs [1,2]. Chronic
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and recurrent bacterial airway infections are the main cause of morbidity and mortality among CF
patients [3].
Staphylococcus aureus is one of the first pathogens that CF patients encounter and the bacterium
with the highest prevalence in the CF population [4,5]. In most cases, a long-term colonization with
individual S. aureus clones is observed [4]. Persistent S. aureus clones tend to form a genetically and
particularly phenotypically heterogeneous population with S. aureus acquisition most likely outside
the hospital with only minor transmission events [6–8]. The genetical diversity is fostered by mutations
and horizontal gene transfer with persistence of dominant lineages and a continuous process of
intra-host adaptation [6,9]. Both geno- and phenotypic changes occur in a time-dependent manner and
accumulate [10,11]. The phenotypic heterogeneity of S. aureus populations in CF patients is intensified
by differences in gene expression, mediated by regulatory mechanisms responding to specific milieu
conditions [6]. The overall trend of S. aureus adaptation in CF airways is directed towards a persistent
and colonizing rather than infecting lifestyle [6,12]. Even in the case of exacerbation, the presence of
S. aureus is restricted to the airways and systemic disease is rarely observed [6]. The preponderance
of colonizing clones results from the suppression of virulence genes for the sake of an intensified
expression of protective factors [6]. Manifold strategies have been described to evade immune response
and antibiotic treatment, including biofilm formation [13,14] emergence of small colony variants
(SCVs) [15–17], intracellular persistence [18], and agr-dysfunction [19], among others [14,20–22].
In children, the colonization with S. aureus is associated with increased inflammatory activity in
the airways and a worse nutritional status [23–25]. For older patients, however, the impact of S. aureus
carriage on lung function and disease progression has not yet been elucidated [26]. This deficit in
knowledge is reflected by the absence of internationally accepted therapeutic guidelines concerning S.
aureus treatment in CF patients [27,28].
In a prospective longitudinal multicenter study, we recently identified the presence of SCVs,
high bacterial density in throat cultures, and elevated IL-6 levels as independent risk factors among
others for worse lung function in patients who were older than 6 years [26]. Further analyses revealed
associations between antibiotic treatment, age, and S. aureus clonal carriage profiles during persistence
assessed by spa-sequence typing of almost 4000 S. aureus isolates from 183 CF patients during a
21-month prospective study [29]. Patients receiving intensive antibiotic therapy regimens more likely
carried S. aureus isolates during persistence, which belonged to only one spa-type [7], while older
patients carried isolates with related spa-types with mutations of the repeat region including deletions,
duplications of repeats or point mutations within repeats, or dominant spa-types cultured [7].
The present analysis continues the evaluation of the abovementioned study intending to identify
genetic bacterial factors associated to clinical deterioration. We hypothesized that either the presence
of specific S. aureus virulence genes or the occurrence of certain phylogenetic backgrounds might be
associated with a deterioration of the patients’ clinical status. To test our hypothesis, we scanned every
isolate for the presence of 25 virulence genes (cap 5/8, chp, cna, clf A/B, sdrC/D/E, fnbA/B, sasG/H, eap, emp,
sea–sej, eta/etb, tst-1, pvl, and hlg) and the agr-specificity groups 1–4, using mono and/or multiplex PCR.
Furthermore, the host response to 19 of these virulence genes was assessed by measuring IgG levels
against the specific proteins by a bead-based flow cytometry technique (xMAP1; Luminex Corporation,
Austin, TX, USA) as previously described [30,31].
2. Results
2.1. Demographics and Statistics
The CF patients participating in the study on average were younger than the German CF
population and showed better lung function [26]. Furthermore, there was an overrepresentation of
nonF508del genotypes and male sex [26]. Fifty-eight patients (30.5%) suffered an exacerbation during
the study period, whereas the clinical status of the remaining 132 (69.5%) subjects did not deteriorate
considerably. Subjects suffering one or more exacerbations showed a poorer lung function (mean 75%
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FEV1% predicted) than healthier patients (mean 84% FEV1% predicted) (p = 0.034 *, Mann–Whitney
U test). In total, 3180 S. aureus isolates were analyzed (1312 from throat cultures, 1065 from nose
cultures, and 803 from sputum cultures). On average, 3.22 (range: 1–12) different S. aureus clones as
determined by spa-typing (Supplementary Materials Table S1 were retrieved from the subjects’ airways.
The majority of patients (108; 57.8%) carried at least one dominant clone that was detected on every
outpatient clinic visit. Six spa-types were most prevalent within this S. aureus population belonging to
the spa-types t084, t012, t091, t015, and t002 (Supplementary Materials Table S2).
2.2. Quantity of Virulence Genes and Clinical Parameters
The starting point for this analysis was the hypothesis that a broad virulence gene profile might
be associated to a deterioration of the patients’ clinical parameters. However, there was no statistical
difference in mean virulence gene quantity between patients suffering from an exacerbation during
the study period (mean of 14.09 virulence genes) and subjects not witnessing exacerbations (mean of
14.29 virulence genes).
2.3. Time-Dependent Quantity of Virulence Genes
The number of virulence genes present in the S. aureus clones populating the patients’ airways
was documented at every outpatient visit, enabling a longitudinal analysis concerning time-dependent
changes in the quantity of virulence genes exhibited by the patients’ S. aureus clones. At the beginning
of the study period, the patients’ S. aureus clones carried on average 14.51 of the 25 virulence genes,
whereas at the end, a mean of 14.17 virulence genes was present. A generalized estimating equation
model was applied using Poisson distribution with log link function. Appropriate model terms for
repeating observations were included using an independent working correlation matrix. Within the
model, we could show a significant decrease in virulence gene quantity (p = 0.029 *, Figure 1) over
time. On average, patients lost 5.6× 10−4 genes per day. Extrapolated (beyond the maximal follow-up
of this study), this would translate to a loss of one gene every five years (exactly, 1.022/5 years).
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2.4. Specific Virulence Genes and Clinical Parameters
The next step consisted in the analysis of a possible association between single virulence genes
and clinical parameters. Therefore, the mean prevalence counts of the individual virulence genes
in different patient subgroups were compared. Patients suffering an exacerbation during the study
period (n = 58) showed similar prevalence counts of the different virulence genes compared to healthier
subjects (n = 132) (Figure 2a–c). The only exception was patients with isolates belonging to agr-type
4, showing a significant overrepresentation among patients with an exacerbation (2.34% vs. 7.72%)
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(p = 0.008 **, Mann–Whitney U test, Figure 2c). Agr-type 1 showed a considerable underrepresentation
among patients witnessing an exacerbation (p = 0.051, Mann–Whitney U test). To narrow the spectrum
of considered subjects to patients with the presumably most severe disease, patients with intensive
antibiotic therapy and exacerbation (n = 35) were compared to the other subjects. In this subgroup,
isolates belonging to agr-type 1 were significantly underrepresented (p = 0.011 *, Mann–Whitney U
test, Figure 2d).
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2.5. Complementary Data Concerning a Humoral Response Towards S. aureus Antigens
S. aureus toxin directed antibody levels in CF patients have been associated to the severity of
exacerbations and decline in FEV1% [32]. Therefore, we measured IgG levels against 19 virulence
factors in serum samples of 182 subjects and compared them to antibody levels of 53 healthy adults
with persistent nasal S. aureus colonization (Supplementary Materials Table S3). While IgG levels
against six antigens were significantly elevated in patients compared to controls (Table 1), IgG levels
against seven virulence factors were significantly associated to a decline in FEV1% predicted (Table 1).
2.6. Phylogeny and Virulence Genes
In the preceding analyses, it became obvious that neither the number of virulence genes present nor
the presence of specific virulence genes was associated to changes in the patients´ clinical parameters.
Nevertheless, the significant differences of the mean prevalence counts of the agr-types 1 and 4 among
patients with an exacerbation suggest an influence of the phylogenetic background on varying degrees
of S. aureus pathogenicity in CF patients. To further pursue these hints, we tested for a link between
agr-type and phylogeny.
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Table 1. Significant IgG levels against S. aureus antigens in patients vs. healthy controls and estimated
effect on forced expiratory volume (1 s) FEV1% a.
Antigen Mean IgG Level AllPatients (±SE) b
Mean IgG Level
Controls (±SE) b p Value c,d
Estimated Effect
on FEV1% e p Value
d
CHIPS 11492 (±220) 11019 (±349) 0.104 −0.00073 0.0185
ClfB 4587 (±222) 4092 (±338) 0.3809 0.002079 <0.0001
Eta 3999 (±447) 2043 (±424) 0.1180 −0.00061 0.0033
Etb 613 (±113) 320 (±94) 0.0032 −0.00700 <0.0001
HlgB 13621 (±174) 9878 (±407) <0.0001 −0.00109 0.0088
LukF 4079 (±133) 2718 (±243) <0.0001 −0.00305 <0.0001
LukS 14097 (±133) 7134 (±524) <0.0001 −0.00169 <0.0001
SdrE 3139 (±201) 1992 (±221) 0.0253 −0.00179 <0.0001
SED 1106 (±118) 1292 (±268) 0.0498 0.001490 0.0377
SEH 2290 (±291) 2174 (±359) 0.0113 −0.00047 0.0986
a Data are partially retrieved from our earlier study [26]; b significant difference of results between 182 patients and
53 healthy controls; c p values of differences between patient and controls groups (Mann–Whitney U test); d adjusted
p-values (Bonferroni correction); and e IgG levels are modelled as continuous factors. Estimated effects are therefore
interpreted as mean change in FEV1% predicted.
Agr-type and virulence gene profile: Clones, which belonged to varying agr-types, differed
significantly concerning the counts of virulence genes (p = 0.001 ***, ANOVA, Supplementary Materials
Figure S1). Agr-type 4 isolates carried less virulence genes compared to isolates belonging to
agr-type 1. Next, the prevalence counts of the specific virulence genes in patients whose S. aureus
clones predominantly belonged to one of the four agr-types were compared. In this analysis, clear
and significant differences in almost all considered virulence genes were found (Kruskal–Wallis test,
Figure 3a). Benjamini and Hochberg (False discovery rate) correction was applied to adjust for multiple
testing. In a final analysis, it was tested for associations between the most prevalent spa- and agr-types.
This revealed that each of the most prevalent spa-types could be clearly assigned to one agr-type
(p < 0.001, Chi-squared test, Figure 3b).
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Figure 3. Association of agr-types and virulence genes or spa-types. (a) Association between agr-types
and virulence gene prevalence counts (Kruskal–Wallis test); the 4 agr-types are indicated as follows:
1 = red, 2 = green, 3 = blue, and 4 = purple. (b) Association between agr-types and prevalent spa-types
(Chi-squared test). Significance levels are indicated by *, **, and ***.
Agr-type and longitudinal virulence gene quantity: In our preceding analysis, we showed that
the counts of virulence genes present in the patients’ S. aureus clones demonstrated a time-dependent
decrease (Figure 1). Reconducting this analysis and taking into account the agr-type of the patients’
isolates revealed clear and significant differences in the process of time-dependent alterations of the
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virulence gene quantity between isolates belonging to the different agr-types (p = 0.0083 **, Wald
test). Isolates belonging to agr-type 1 and 3 showed a longitudinal decline in virulence gene quantity,
whereas the virulence gene number in isolates belonging to agr-type 2 slightly increased and agr-type 4
isolates remained stable in virulence gene numbers (Figure 4).
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Figure 4. Longitudinal development of virulence gene counts depending on agr-type (Wald Test).
Colored lines indicate the averaged loss of virulence genes over time for patient groups showing a
predominance of an agr-type (blue = agr-type 1, red = agr-type 2, green = agr t e 3, a ell
agr-t ). c l r ots indicate the virulence gene quantity of the individual S. aure s clones at
different dates during the study. Significance levels are indicated by *, **, and ***.
2.7. Cluster Analyses
Since the isolates belonging to the different agr-types significantly varied in the prevalence of
many virulence genes (Figure 2), it was considered that certain combinations of virulence genes rather
than single virulence genes might be associated to a deterioration in clinical parameters. To test this
hypothesis, a distance matrix was created deploying Euclidian distance and then hierarchical clustering
via ward linkage was applied. The virulence gene profiles were grouped into four association clusters,
implying that the virulence gene profiles of patients within a cluster are more similar to each other
than to virulence gene profiles of other clusters. In a second step, we analyzed for associations between
these clusters and the different agr-types, rendering significant results (p = 0.001 ***, Chi-squared test,
Figure 5). Next, it was investigated whether exacerbation rates differed significantly between the four
virulence gene clusters, which was not the case.
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2.8. Virulence Gene Plasticity and Environmental Stress
Environmental stress consisting of antibiotic therapy and/or immune response has been shown
to be a powerful inducer of hgt, in particular of bacteriophage mediated transduction [33–35]. Since
this process can entail clinical consequences and can be induced iatrogenically, the data were checked
for hints pointing towards stress-induced virulence gene plasticity in the study population. The
patients were divided using the “environmental stress high/low” parameter. Patients assigned to
the “environmental stress high” group showed at least one exacerbation during the study period
and received intensive antibiotic treatment; 633 S. aureus isolates of 35 patients were exposed to
high amounts of environmental stress. There were significant differences in plasticity for three out
of 25 tested virulence genes (chp, eta, etb), all of them showing increased plasticity in case of high
environmental stress (Mann–Whitney U test, Figure 6).
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3. Discussion
A prospective longitudinal multi-centre study consisting of 195 patients receiving treatment in
17 specialized CF centres was conducted to identify genetic bacterial factors associated to clinical
deterioration in the patient cohort. It was tested whether the presence of specific S. aureus virulence
genes or the occurrence of certain phylogenetic backgrounds were linked to differing clinical status of
the subjects. Furthermore, the data were analysed for longitudinal changes in the S. aureus virulence
gene composition and stress dependent virulence gene plasticity.
The analyses revealed several interesting findings that will be discussed in the following.
3.1. Specific Virulence Genes and Clinical Parameters
None of the virulence genes characteristic of S. aureus (tst-1 and lukS/F, among others) was
associated to exacerbations. This finding supports the hypothesis that, given no susceptible host, the
presence of single virulence genes is not associated with a significant increase in the overall severity of
S. aureus infections and, consequently, that a screening for such “super weapons” is not required [36–39].
These results, however, only apply to S. aureus disease in CF patients and neither could nor should
be generalized. Moreover, there are significant regional differences in the prevalence counts of the
various virulence genes. For instance, community-acquired methicillin-resistant S. aureus (CA-MRSA)
strains, which mostly carry the Panton-Valentine leucocidin (PVL, lukS/F), are rare in Germany while
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widespread in the US [40–42]. The significant differences in the prevalence counts of the agr-types
1 and 4 between patients with and without exacerbations most likely did not arise from differing
intrinsic gene regulatory activities of the varying agr-types, since the agr-system has been described to
be inactive in CF patients most of the times [19,43]. Rather, the observation of widespread agr-inactivity
or dysfunction in CF airways suggests a link between the agr-system and S. aureus phylogenetic
background as an explanation for differing gene prevalence counts in exacerbating patients [39].
3.2. Phylogeny and Pathogenicity
The identification of the different agr-types as the only parameter that was associated to the
subjects’ clinical status supports the hypothesis that the basic unit of S. aureus pathogenicity is not
the presence of specific single virulence genes but most likely certain combinations of genes linked
to a clone’s phylogenetic background [39,44]. The phylogenetic indicator function of the agr-system
is highlighted by further analyses, revealing considerably varying virulence gene profiles between
patients whose S. aureus clones differed concerning their agr-types (Figure 3a) and the observation that
each prevalent spa-type could be clearly assigned to one agr-type (Figure 3b). The results of the cluster
analyses added further coherence to these findings: the different agr-types showed a significantly
unequal distribution between the four virulence gene clusters (Figure 5).
3.3. Longitudinal Decline in Virulence Gene Quantity
The analyses revealed a significant time-dependent decline in the number of virulence genes
exhibited by the subjects’ S. aureus clones (Figure 1). The decrease may seem negligible at first glance;
however, it has to be taken into account that this analysis is highly limited in two dimensions. On the
one hand, it only covers a short cutout of the longstanding interaction between S. aureus and its human
host. On the other hand, only a small fraction of the extensive S. aureus virulence genome is included.
Thus, a hypothetical extrapolation concerning follow-up time and considered virulence genes would
put the results into a different perspective. Hence, this finding is considered as a clear hint towards a
longitudinal decline of S. aureus virulence gene quantity in CF patients and thus indicates that S. aureus
shows not only high phenotypic diversity and increased degrees of gene plasticity in CF airways but
also long-term changes in its (virulence) gene composition. The finding is also consistent with the
persistent and colonizing rather than infectious lifestyle, which S. aureus displays in CF patients [6].
Similar processes have also been proven for chronic P. aeruginosa infection in CF patients [45,46]. The
gradual loss of virulence genes could be beneficial for the bacterium concerning the evasion of host
defenses, since many virulence factors are targets for the immune system as obvious by mounting of
specific IgG against such virulence factors (Table 1) [45]. Future research has to show whether there is
evidence for this trend on the level of a more comprehensive virulence gene profile analysis using
whole genome sequencing (WGS). While Azarian et al. used WGS to investigate intra-host diversity of
sequential MRSA isolates in four CF patients, the authors focused in their analysis, for which they
used sequencing data of a mean of 21 isolates per patient from a mean period of 1403 days on the
evidence of switched intergenic regions, allele frequency, and single nucleotide polymorphisms but
not the presence or absence of special virulence genes [9]. Therefore, it is not possible to compare their
data with our analysis.
3.4. Virulence Gene Plasticity and Environmental Stress
In this analysis, the virulence gene plasticity was used as a surrogate parameter to estimate the
potential for hgt. It is considered a reasonable parameter for this purpose since genome plasticity
forms a necessary precondition for hgt. Furthermore, surroundings that are associated to increased
rates of virulence gene plasticity in the data have also been identified as inductors of hgt [47,48]. The
analyses revealed significantly increased plasticity rates for several genes in the presence of high
environmental stress (Figure 6). These results are in line with research having identified environmental
stress as an inducer of hgt and suggest an iatrogenic and host-related impact on the S. aureus virulence
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genome [34,35]. According to the “insurance hypothesis”, genomic plasticity is a necessary prerequisite
for adaptation to changing and challenging surroundings [49]. That these surroundings themselves
increase the potential for hgt is an important fact that treating physicians should be aware of. Particularly
sub-inhibitory concentrations of antibiotics, which are often observed to occur in CF patients, have
been shown to be powerful inducers of hgt [50].
3.5. Strengths and Limitations of the Study and Analyses
The study population differs from the German CF population concerning age, sex, lung function,
and genotype [26]. The “No P. aeruginosa” inclusion criterion is considered to be the reason for the
subjects’ young age, since with increasing life span patients become more prone to colonization and
infection with P. aeruginosa [5]. The young age in turn presumably accounts for the subjects’ better lung
function compared to the German CF population, since it is an age-correlated parameter characterized
by a longitudinal decline [51,52]. The “No P. aeruginosa” criterion presumably also accounts for the
increased prevalence of non-F508del genotypes since those genotypes have been shown to exhibit
a delayed colonization by P. aeruginosa compared to F508del homozygous patients [53]. There are
no clear hints that these demographic incongruities go along with a limited transferability of the
findings to the basic CF population. Both groups show a similar annual decline in lung function and
thus do not seem to differ substantially in the course of the disease [26,51,52]. A shortcoming of the
study is the rather short follow-up time of app. 80 weeks, which only covers a narrow cutout of the
long-lasting interaction between S. aureus and its human host. Moreover, the analyses are primarily
based on genetic data. Complementary proteomic data would be desirable, since differences in gene
expression contribute to the high level of phenotypic diversity among S. aureus clones [54]. Especially
the diversity of the S. aureus exoproteome is considered to be relevantly shaped by gene regulation
mechanisms [55,56].
4. Conclusions
The results of our prospective multicenter study suggest that the phylogenetic background defines
S. aureus pathogenicity rather than specific virulence genes. The significantly increased gene plasticity
rates in the presence of environmental stress suggest an iatrogenic and host influence on S. aureus
genome plasticity. The longitudinal loss of virulence genes might reflect the adaptation process directed
towards a persistent and colonizing rather than infecting behavior of S. aureus in CF patients.
5. Material and Methods
5.1. Study Design
The data underlying this analysis were generated during an prospective multicenter study
(ClinicalTrials.gov, NCT00669760). An ethical statement was obtained at the main study center with the
central laboratory in Münster, Germany (2007-496-f-S) on the 1 June 2009. Written informed consent
was obtained from all patients and from parents if patients were younger than 18 years.
The study population consisted of 195 CF patients receiving treatment in 16 German and one
Austrian CF center. CF patients older than six years whose airways were persistently colonized by
S. aureus during the study period (more than 50% of specimen positive for S. aureus) were included
into the trial. The follow-up time was on average 80 weeks, with a mean of seven outpatient clinic
visits per patient, usually performed at an interval of three months. Inclusion criteria were the
presence of a minimum of two airway cultures positive for S. aureus during an interval of six months
in the year before study enrollment, and if more than four cultures were available, at least 50% of
them had to harbor S. aureus. To prevent possible confounding caused by the presence of bacteria
other than S. aureus, potential subjects showing specimens positive for Pseudomonas aeruginosa and/or
Burkholderia cepacia complex (BCC) were to be ruled out a priori. At each outpatient visit, nasal and
throat and/or sputum samples were retrieved and sent to the central study laboratory in Münster,
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where the material was cultivated following standardized procedures for CF airway specimens as
described elsewhere [57]. Furthermore, antibiotic regimens and clinical parameters were monitored
and documented longitudinally. For a more detailed description of the study, see Junge et al. [26]. The
obtained S. aureus isolates (n = 3893) were distinguished deploying the spa-typing method [58]. The
“Based upon repeat pattern” method (BURP, Ridom StaphType software) was used to analyze the
clonal relatedness of different spa-types differentiating 266 spa types (Supplementary Materials Tables
S1 and S2) [29,59]. In this analysis, every isolate was scanned for the presence of 25 virulence genes
and the 4 agr-specificity groups, using single and multiplex PCR.
In the present study, 3180 S. aureus isolates obtained from 190 patients were analysed; five subjects
were excluded because no persistent S. aureus has been detected in their specimens; and 713 isolates of
the former 3893 isolates [33] were disregarded due to identity of isolates in regard of the same visit,
sample (nose or throat swab or sputum), spa-type, and virulence gene profile.
5.2. Virulence Gene Profiles
The obtained S. aureus isolates (n = 3180) were scanned for the presence of 25 virulence genes
and the four agr-specificity groups (cap 5/8, chip, cna, clf A/B, sdrC/D/E, fnbA/B, sasG/H, eap, emp, sea–sej,
eta/etb, tst-1, pvl, hlg, and agr), using single and multiplex PCRs as described elsewhere (Supplementary
Materials Table S4 [60–67]).
5.3. Parameters
The study provided an extensive data set, consisting on the one hand of the patients’ clinical
data and on the other hand of the results of the microbiological analyses. Since the aim of this
analysis was to screen for correlations between these two different data domains, reasoned parameters
were to be established to render the data accessible for statistical analysis, while at the same time,
oversimplification had to be avoided to generate data that is of use for clinicians. The parameters were
chosen and defined as follows:
5.3.1. Exacerbation
The treating physicians monitored the patient’s clinical status according to the Fuchs criteria
(change in sputum/sinus discharge, new or increased dyspnea/cough/hemoptysis/malaise/weight
loss/sinus tenderness, temperature over 38 ◦C, radiographic changes indicative of lung infection, and
decrease in pulmonary function by 10%) [68]. If at one visit four or more Fuchs criteria were met, the
respective patient was assigned to the “exacerbation” group.
5.3.2. Lung Function
Spirometric lung function testing was conducted on every outpatient clinic visit. Lung function
was expressed as forced expiratory volume (1 s) (FEV1) percent of normal. Comparison with a healthy
cohort was achieved by using the Quanjer prediction model [69]. During the study’s follow-up, lung
function changes over time were negligible. Thus, the mean lung function (FEV1%) throughout all
outpatient clinic visits was calculated for every patient.
5.3.3. Virulence Gene Prevalence Counts
To analyze for associations between the presence of specific virulence genes and a patient’s
clinical outcome, the calculation of individual virulence gene prevalence counts was necessary, which
display the percentage of isolates in which the respective virulence gene was present throughout the
study period.
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5.3.4. Quantity of Virulence Genes
In addition to a possible clinical impact of single virulence genes, it was also evaluated whether a
broad or narrow spectrum of virulence genes in general correlated with changes in clinical outcomes.
Thus, it was reviewed for every visit how many of the 25 virulence genes were present in the patients’
S. aureus clones. This count was conducted in a complementary way, meaning that, at every visit, each
proven virulence gene was only counted once per clone. This parameter also enabled a longitudinal
analysis of a possible time-dependent change in the number of virulence genes incorporated by the
S. aureus clones populating the patients’ airways.
5.3.5. Agr-Type
The accessory gene regulator (agr) not only represents one of S. aureus’s most important virulence
regulators but also is tightly linked to the bacteria’s phylogenetic background [39,44,70,71]. To elicit
possible relations between agr-type, virulence gene prevalence counts, and spa-types, the isolates of
patients were analyzed in terms of dominance of a specific agr-type. To belong to the group with
dominant agr-types, at least a two-third majority of patients’ isolates had to belong to one of the
four agr-types, which was the case for 154 patients. Patients without a dominance of one agr-type
(36 subjects) were excluded from further analyses regarding this parameter.
5.3.6. Environmental Stress
Previous research has shown an impact of antibiotic therapy and host immune response on
genomic variability and horizontal gene transfer (hgt) [33,35,50]. Thus, the parameter “environmental
stress” was established, which includes all patients who suffered an exacerbation during the study
period and received intensive antibiotic therapy. The latter was defined as ≥7 cycles of antibiotic
therapy during the study period. The environmental stress parameter was used to compare gene
plasticity and hence the potential for hgt in S. aureus isolates that were exposed to high amounts of
environmental stress to isolates subsisting in a less challenging environment.
5.3.7. Virulence Gene Plasticity and Horizontal Gene Transfer
To quantify the plasticity of the virulence genes, the virulence profiles of the patients’ S. aureus
clones were compared from visit to visit. Events of gain and loss of virulence genes were counted,
resulting in a value for every virulence gene of every clone of each subject, representing its variability
in this specific clone of this specific patient. To receive a variability value for every virulence gene for
every patient independent of the different clones, the cumulative sum of genetic switch events of each
clone of the patient was calculated, resulting in a variability value for every virulence gene for each
patient, which later was set into relation to other parameters. The virulence gene plasticity was used as
a surrogate parameter to estimate the potential for hgt.
5.3.8. Antistaphylococcal Antibodies
IgG antibody levels were quantified applying a bead-based flow cytometry technique (xMAP ®;
Luminex Corporation) as previously described [30,31]. For further information, see Junge et al. [26].
5.4. Statistical Analyses
Study data were analyzed using descriptive and inductive statistical methods. For data description,
absolute and relative frequencies were used for categorical variables while continuous parameters
were described by mean and standard deviation or by median and interquartile range. To check for
normal distribution, histogram plots and the Kolmogorov–Smirnov test were applied. For group
comparisons, t-tests and ANOVA were applied. In the case of non-normal distributions nonparametric
methods (e.g., Mann–Whitney U tests) were applied. Associations between categorical variables were
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tested with Chi-squared tests. Regression coefficients were tested using the Wald-test statistic. Further
details of the applied statistical methods are given in line with the results of the presented analyses.
The statistical analyses were conducted using SPSS (IBM Corp. Released 2017. IBM SPSS Statistics
for Windows, Version 25.0. Armonk, NY, USA: IBM Corp.). The significance level for all performed
statistical tests is 0.05. All statistical tests have to be considered exploratory. Results, thus, might need
to be validated in prospective trials. Significant p-values, thus, indicate noticeable effects and not
significant results in a confirmatory sense. For illustrations, significance levels are indicated by *, **,
and ***.
Supplementary Materials: The following are available online at http://www.mdpi.com/2072-6651/12/5/279/s1,
Figure S1: Agr-type vs. virulence gene count, Table S1: spa-types of all S. aureus isolates; Table S2: Prevalent
spa-types; Table S3: Prevalent spa-types; Table S4: Primers for single and multiplex PCRs.
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